On June 20, 2024 4 Redx Pharma (JPJ:REDX), the clinical-stage, small molecule biotechnology company,
reported that Phase 2 data from zamaporvint (RXC004), a Porcupine inhibitor targeting Wnt-ligand dependent GI cancers, will be presented at the European Society for Medical Oncology Gastrointestinal Cancers Congress (ESMO GI), 26-29th June, Munich, Germany (Press release, Redx Pharma, JUN 20, 2024, View Source [SID1234644454]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Zamaporvint is a potent, selective, orally-active Porcupine inhibitor in development for hard-to-treat GI cancers. The principal efficacy hypothesis for zamaporvint is for use in combination, which has been investigated in Phase 2 signal searching patient cohorts with anti-PD-1 therapy. Monotherapy for single agent activity has also been investigated. The PORCUPINE study was in genetically-selected patients with microsatellite stable metastatic colorectal cancer (MSS mCRC) as monotherapy and immuno-oncology combination (clinicaltrials.gov NCT04907539). The PORUPINE2 study was in all-comers biliary tract cancer as monotherapy and immuno-oncology combination, and in genetically selected pancreatic cancer as monotherapy (clinicaltrials.gov NCT04907851).

The data will be presented in two posters, one on the PORCUPINE study and one on the PORCUPINE2 study. Notably, these data demonstrate that zamaporvint, in combination with an anti-PD-1 agent in genetically-selected patient populations has the potential to improve upon efficacy outcomes achieved with standard of care alone.
Details of the poster presentations are as follows:

1)
Abstract Title: Phase 2 results of the Porcupine (PORCN) inhibitor zamaporvint
(RXC004) in genetically selected microsatellite stable colorectal
cancer patients
Session Title: Poster Session
Date/Time: Thursday 27 June 3:35 – 4:30pm CEST
Poster Number: 37P

2)
Abstract Title: Phase 2 results of the porcupine (PORCN) inhibitor zamaporvint
(RXC004) in patients with pancreatic and biliary tract cancer
Session Title: Poster Session
Date/Time: Thursday 27 June 3:35 – 4:30pm CEST
Poster Number: 391P
A copy of the posters will be made available on Company’s website following the presentation at:
View Source